Leritrelvir

Leritrelvir
Identifiers
	IUPAC name (3S,3aS,6aR)-2-[(2S)-2-cyclohexyl-2-[(2,2,2-trifluoroacetyl)amino]acetyl]-N-[(2S)-4-(cyclopentylamino)-3,4-dioxo-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide;
CAS Number	2923310-64-7;
PubChem CID	167713195;
ChemSpider	128922060;
ChEMBL	ChEMBL5422898;
Chemical and physical data
Formula	C31H44F3N5O6
Molar mass	639.717 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CCC(CC1)[C@@H](C(=O)N2C[C@@H]3CCC[C@@H]3[C@H]2C(=O)N[C@@H](C[C@@H]4CCNC4=O)C(=O)C(=O)NC5CCCC5)NC(=O)C(F)(F)F;
	InChI InChI=1S/C31H44F3N5O6/c32-31(33,34)30(45)38-23(17-7-2-1-3-8-17)29(44)39-16-19-9-6-12-21(19)24(39)27(42)37-22(15-18-13-14-35-26(18)41)25(40)28(43)36-20-10-4-5-11-20/h17-24H,1-16H2,(H,35,41)(H,36,43)(H,37,42)(H,38,45)/t18-,19-,21-,22-,23-,24-/m0/s1; Key:ICGMMLTUQDVAST-HEZDJTGRSA-N;

Leritrelvir (RAY1216) is an antiviral drug which acts as a 3C-like protease inhibitor. It was developed in China for treatment of COVID-19.^[1]^[2]^[3]^[4]

References

^ Janin YL. On the origins of SARS-CoV-2 main protease inhibitors. RSC Med Chem. 2023 Oct 13;15(1):81-118. doi:10.1039/d3md00493g PMID 38283212
^ Chan CC, Guo Q, Chan JF, Tang K, Cai JP, Chik KK, Huang Y, Dai M, Qin B, Ong CP, Chu AW, Chan WM, Ip JD, Wen L, Tsang JO, Wang TY, Xie Y, Qin Z, Cao J, Ye ZW, Chu H, To KK, Ge XY, Ni T, Jin DY, Cui S, Yuen KY, Yuan S. Identification of novel small-molecule inhibitors of SARS-CoV-2 by chemical genetics. Acta Pharm Sin B. 2024 Sep;14(9):4028-4044. doi:10.1016/j.apsb.2024.05.026 PMID 39309487
^ Cao Q, Ding Y, Xu Y, Li M, Zheng R, Cao Z, Wang W, Bi Y, Ning G, Xu Y, Zhao R. Small-molecule anti-COVID-19 drugs and a focus on China's homegrown mindeudesivir (VV116). Front Med. 2023 Dec;17(6):1068-1079. doi:10.1007/s11684-023-1037-3 PMID 38165534
^ Zheng B, Zhao Q, Yang W, Feng P, Xin C, Ying Y, Yang B, Han B, Zhu J, Zhang M, Li G. Small-molecule antiviral treatments for COVID-19: A systematic review and network meta-analysis. Int J Antimicrob Agents. 2024 Mar;63(3):107096. doi:10.1016/j.ijantimicag.2024.107096 PMID 38244811